Rueda, A, Garcia-Leon, A, Arena, LA, Mendoza, JI, Avino, A, Fabrega, C, Eritja, R, Paez, D, Alba-Castellon, L, Vazquez, E, Villaverde, A, Mangues, R, Casanova, I, Unzueta, U. Conjugation strategy shapes antitumor efficacy and enables dose-sparing in non-antibody protein nanoconjugates. Materials Today Bio. 2026; 36DOI:10.1016/j.mtbio.2025.102698. PMID:41560806. IF:10.200(Q1/1D).

Borrego, MR, Lopez-Bravo, DP, Vila, MM, Pérez-García, JM, Fernández, M, Tormo, SB, García-Saenz, JA, Lema, L, Garau, I, Cortez, P, Torres, AA, Conejo, EA, Calvo, I, Ferrer, N, Blancas, I, Amillano, K, Santasusagna, S, Benderra, MA, Alcalá-Lopez, D, Antonarelli, G, Sampayo-Cordero, M, Llombart-Cussac, A, Cortés, J. Liposomal irinotecan in patients with HER2-negative breast cancer and brain metastases: The PHENOMENAL phase 2 study. EUROPEAN JOURNAL OF CANCER. 2026; 233DOI:10.1016/j.ejca.2025.116161. PMID:41371050. IF:7.100(Q1/2D).

Toledano-Fonseca, M, Cano-Osuna, MT, Elez, E, Soto-Alsar, J, Paáez, D, Fernández-Montes, A, Graña, B, Salud, A, Yubero, A, Macías, I, Quintero, G, López-López, C, Fernández-Rodríguez, T, García-Ortiz, MV, Sastre, J, García-Alfonso, P, Rodríguez-Ariza, A, Aranda, E. Circulating hsa-miR-29c-3p and VEGF-A levels predict the response to FOLFIRI plus aflibercept in elderly metastatic colorectal cancer patients. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2026; 56(1)DOI:10.1111/eci.70103. PMID:40747746. IF:3.600(Q1/2D).

Mirallas, O, Ruiz-Pace, F, Velilla, G, Gómez-Puerto, D, Gorria, T, Yaringaño, J, Martínez-Monino, A, López-Valbuena, D, Vaz, MA, Hernandez, A, Martínez-Saez, E, Sorolla, MA, Castro-Henriques, M, Bardaji, JL, Di Muzio, A, Gallego, O, Martínez-García, M, Domenech, M, Carles, J, Balaña, C, Pineda, E, Dienstmann, R, Vieito, M, Sepúlveda, JM. Clinical actionability in gliomas revealed by real-world next-generation sequencing: a multicentric study. npj Precision Oncology. 2026; 10(1)DOI:10.1038/s41698-025-01247-3. PMID:41495434. IF:8.000(Q1/2D).

O'Byrne, K, Esteban, E, Lee, CL, Hegmane, A, Volovat, C, Lo Russo, G, Ziogas, D, Atmaca, A, Sebastian, M, Majem, M. A phase III placebo-controlled study of eftilagimod alfa plus pembrolizumab and chemotherapy in metastatic non-small cell lung cancer. Future Oncology. 2025; 21(30)DOI:10.1080/14796694.2025.2597404. PMID:41383151. IF:2.600(Q3/6D).

Salazar, J, Arranz, MJ, Martin-Broto, J, Serra, M, Palmerini, E, Martínez-García, J, Juan-Ribelles, A, Andion, M, Martinez-Trufero, J, Gutiérrez, G, Echebarria-Barona, A, Vaz-Salgado, MA, Regueiro, A, Alvarez, R, Valverde, C, Luna, P, Blay, P, Sebio, A. VEGF Signaling Pathway Germline Polymorphisms as Prognostic Pharmacogenetic Biomarkers in Localized High-Grade Osteosarcoma Patients from the GEIS-33 Protocol. Pharmaceuticals. 2025; 18(12)DOI:10.3390/ph18121855. PMID:41471344. IF:4.800(Q1/2D).

Tsuboi, M, Wakelee, H, Spicer, JD, Gao, S, Liberman, M, Kato, T, Chen, KN, Dooms, C, Majem, M, Martinengo, GL, Bylicki, O, Abreu, DR, Halmos, B, Jones, DR, Chaft, J, Reck, M, Jense, E, Keller, SM, Samkari, A, Garassino, MC. Perioperative pembrolizumab in early-stage non-small-cell lung cancer (NSCLC): 5-year follow-up from the KEYNOTE-671 global study and Asian subgroup. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.10.607. PMID:. IF:65.400(Q1/1D).

Molina-Pérez, MA, Martínez-Recio, S, Barba, A, Portu, M, Sanz-Beltran, J, Majem, M. Letetresgene autoleucel in advanced non-small cell lung cancer: a step towards truly personalized immunotherapy?. Translational Lung Cancer Research. 2025; 14(11)DOI:10.21037/tlcr-2025-866. PMID:41367561. IF:3.500(Q1/3D).